FDA Brief

Warning letters Drugs

FDA warning letter to

JulyMD

High riskIssued Sep 9, 2025Posted Sep 16, 2025Center for Drug Evaluation and Research (CDER)

FDA warned JulyMD that its website sold compounded semaglutide with misleading claims comparing it to Wegovy and Ozempic.

What happened

FDA reviewed JulyMD's website at https://julymd.com in August 2025. It found the site offered compounded drug products, including semaglutide, and claimed the compounded semaglutide had the same active ingredient as Wegovy and Ozempic at a fraction of the price. FDA said compounded drugs are not FDA-approved, so these claims are false or misleading and make the products misbranded.

What FDA found

  1. The website claimed compounded semaglutide had the same active ingredient as Wegovy and Ozempic and was an affordable alternative, implying the compounded product was the same as FDA-approved drugs.

    FDCA section 502(a) [21 U.S.C. § 352(a)]
  2. The website's advertising and promotion of compounded semaglutide were false or misleading for making those equivalence claims even though compounded drugs are not FDA-approved.

    FDCA section 502(bb) [21 U.S.C. § 352(bb)]
  3. The misbranded compounded semaglutide products were introduced or delivered for introduction into interstate commerce.

    FDCA section 301(a) [21 U.S.C. § 331(a)]

What FDA wants

FDA tells JulyMD to take immediate action, including ceasing the misleading claims, and to respond in writing within 15 working days to CDER's Office of Compounding Quality and Compliance with the steps taken, how recurrence will be prevented, and supporting documentation.

Who should pay attention

  • telehealth and online pharmacies selling compounded semaglutide
  • compounding pharmacies and marketers comparing products to FDA-approved GLP-1 drugs
  • platforms or brands hosting or promoting compounded drug offers

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk